ABT-263 (Navitoclax), Inhibitor

ABT-263 (Navitoclax)

Cat. Num. AAA384108

• Purity: >98%
• Synonyms: ABT-263 (Navitoclax); ABT263; inhibitor

• Purity/Purification: >98%
• Form/Format: Powder
• Concentration: 0.1 mM: 10.26 mL (1 mg); 51.3 mL (5 mg); 102.61mL (10 mg); 0.5 mM: 2.05 mL (1 mg); 10.26 mL (5 mg); 20.52 mL (10 mg); 1 mM: 1.03 mL (1 mg); 5.13 mL (5 mg); 10.26 mL (10 mg); 5 mM: 0.21 mL (1 mg); 1.03 mL (5 mg); 2.05 mL (10 mg) (varies by lot)

• CAS Number: 923564-51-6
• Formula: C47H55ClF3N5O6S3
• SMILES: CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)N[C@H](CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C
• Actions: Inhibitor
• Solubility (DMSO): 100 mg/mL (102.6 mM)
• Solubility (Ethanol): <1 mg/mL (<1 mM)
• Solubility (Water): <1 mg/mL (<1 mM)
• Availability: We cannot ship this item to Switzerland, Italy, Germany, France and Austria.
• Preparation and Storage: at -20 degree C 3 years Powder

Chemical Structure

Related Product Information for ABT-263 (Navitoclax), inhibitor

ABT-263 also called Navitoclax is a potent and orally bioavailable Bcl-2 family inhibitor (Ki's of <1 nmol/L for Bcl-2, Bcl-xL, and Bcl-w).ABT-263 maintains a high affinity for Bcl-xL, Bcl-2, and Bcl-w, (Ki ≤1 nmol/L), but binds more weakly to Mcl-1 and A1.

References

Momeny M, .et al. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells, Cell Oncol (Dordr), 2019, Apr 25 PMID: 31025257
Anderson R, .et al. Length-independent telomere damage drives postmitotic cardiomyocyte senescence, EMBO J, 2019, Feb 8. pii: e100492 PMID: 30737259
Shinya Ishida, .et al. Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2, Oncotarget, 2018, Jun 1; 9(42): 26834-26851 PMID: 29928488
Rhys Anderson, .et al. Length-independent telomere damage drives cardiomyocyte senescence, bioRxiv, 2018, 2018
Ryuta Mikawa, .et al. Elimination of p19ARF-expressing cells protects against pulmonary emphysema in mice, Aging Cell, 2018, Oct; 17(5): e12827 PMID: 30058137
Joo Sang Lee, .et al. Harnessing synthetic lethality to predict the response to cancer treatment, Nat Commun, 2018, 9: 2546 PMID: 29959327
Toshiyuki Sumi, .et al. Survivin knockdown induces senescence in TTF-1-expressing, KRAS-mutant lung adenocarcinomas, Int J Oncol, 2018, Jul; 53(1): 33-46 PMID: 29658609
Wei TW, .et al. Aurora A and NF-κB Survival Pathway Drive Chemoresistance in Acute Myeloid Leukemia via the TRAF-Interacting Protein TIFA, Cancer Res, 2017, Jan 15;77(2):494-508 PMID: 28069801
Yusuke Takagi, .et al. SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway, Cancer Sci, 2016, Sep; 107(9): 1270-1280 PMID: 27348272
Matsumoto M, .et al. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells, Biochem Biophys Res Commun, 2016, Apr 29;473(2):490-6 PMID: 26996126